What We do

---

 Diversified real estate company specializing in the development, planning, and acquisition of new and existing commercial properties. Our focus includes light industrial, warehouse and logistics, advanced air mobility, hospitality, and entertainment venues. We aim to create sustainable economic and social impact in the communities we operate in. 

 Venture capital and private equity investment and development company focused on the energy industry. We identify, develop, and participate in investment opportunities based on sustainable energy transition strategies, supporting the development and scaling of innovative energy ventures. Our focus includes technological and infrastructure solutions for improving efficiencies and environmentally friendly operations, as well as industrial project development for liquefied natural gas (LNG) processing, marketing, and transportation. 

Early-stage investment organization focused on identifying challenging global problems and supporting entrepreneurs with innovative technological solutions. We invest in new and established business models to build transformative companies that significantly encourage positive impact and address global challenges. Our focus includes sustainable development in industrial, TMT, Ecommerice, FinTech, FoodTech, HealthTech, Entertainment, and eSports.

Asset and investment management company exclusively for Challenger Group that also operates as a project developer to research, plan, and originate principal investments,  and manage and support critical business functions for private market investments in Energy, TMT, Ecommerce, FinTech, FoodTech, Health Tech, Entertainment, Hospitality, and Real Estate, in partnership with strategic and financial partners. 

Bio + Health focused investment firm that backs companies   companies extending human healthspan and redefining wellness. We invest across Longevity, Biomedical Innovation, HealthTech, and Beauty Tech—partnering with founders who combine rigorous science with scalable business models. Our edge: deep clinical networks, operational expertise in regulatory pathways, and patient-centric capital that accelerates time-to-market without compromising scientific integrity.

We curate our portfolio to back companies at the convergence of proven biology and emerging delivery models—where scientific rigor meets market gaps in prevention, extended healthspan, and patient-centric care.